Clinical Trial

Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A Phase 2 Study of evorpacept (ALX148) in Combination With pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2020-12-17; most recent amendment 2025-07-30.
Status change: Recruiting → Active, Not Recruiting 2024-07-18
Status change: Not Yet Recruiting → Recruiting 2021-05-14
Trial Details
NCT Number NCT04675333
Lead Sponsor ALX Oncology Inc.
Collaborators: Merck Sharp & Dohme LLC
Conditions Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Enrollment 172 participants
Start Date 2021-05-10
Primary Completion 2025-03-03 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-08-03